Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie narrowly topped second-quarter expectations Friday and reaffirmed its earnings outlook. But AbbVie stock fell early.

AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook

Shares of AbbVie Inc. ABBV, -0.93% were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $924 million, or 51 cents per share, in the second quarter of this year, compared with $766 million, or 42 cents per share, in the same quarter a year ago.

AbbVie reports an increase in second-quarter revenue, led by sales of Humira

AbbVie Inc has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.

AbbVie sets aside $2 billion to settle U.S. opioid claims

Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37, an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14 Per Share related to Acquired IPR&D and Milestones Expense 1  Delivers Second-Quarter Net Revenues of $14.583 Billion, an Increase of 4.5 Percent on a Reported Basis and 6.1 Percent Operationally  Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.207 Billion, an Increase of 17.8 Percent on a Reported Basis, or 19.2 Percent on an Operational Basis; U.S. Humira Net Revenues Were $4.664 Billion, an Increase of 9.6 Percent; Internationally, Humira Net Revenues Were $699 Million, a Decrease of 13.8 Percent on a Reported Basis, or 7.3 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.252 Billion; Global Rinvoq Net Revenues Were $592 Million; Combined Global Skyrizi and Rinvoq Net Revenues Were $1.844 Billion   Second-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.650 Billion, a Decrease of 9.1 Percent on a Reported Basis, or 7.9 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $1.145 Billion, a Decrease of 17.1 Percent, with U.S. Net Revenues of $862 Million and International Profit Sharing of $283 Million; Global Venclexta Net Revenues Were $505 Million   Second-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.658 Billion, an Increase of 13.7 Percent on a Reported Basis, or 15.2 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $678 Million; Vraylar Net Revenues Were $492 Million   Second-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.371 Billion, a Decrease of 4.4 Percent on a Reported Basis, or 2.1 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $695 Million; Global Juvederm Net Revenues Were $344 Million, Unfavorably Impacted by COVID-19 Restrictions in China and Suspension of Aesthetics Operations in Russia   Confirms 2022 Adjusted Diluted EPS Guidance Range of $13.78 - $13.98, which Includes an Unfavorable Impact of $0.23 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2022 NORTH CHICAGO, Ill., July 29, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2022.

AbbVie Reports Second-Quarter 2022 Financial Results

Scotts Miracle-Gro

Are These Good Long Term Investments Into Cannabis? The post Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August

AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?

Should You Buy AbbVie Ahead Of Earnings?

There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.

AbbVie Q2 Preview: Can Shares Retain Their Strength?

Chevron

Procter & Gamble

Exxon Mobil

A financial advisor can help you understand the advantages and disadvantages of investment properties.

Earnings Previews: AbbVie, Chevron, Exxon Mobil, Procter & Gamble

Submissions are supported by three Phase 3 clinical trials demonstrating upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment1-4 Safety results were generally consistent with the known safety profile of upadacitinib, with no new safety risks observed1-8 Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea and abdominal pain9,10 NORTH CHICAGO, Ill. , July 27, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]) for the treatment of adult patients with moderately to severely active Crohn's disease.4,11 "Crohn's disease can be debilitating and have a significant impact on a person's daily life," said Neil Gallagher, M.D.

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's Disease

Activision Blizzard

Enphase Energy

Enterprise Products Partners

Energy Transfer LP Unit

Lockheed Martin

Merck

Wells Fargo

Young investors are taking their share of lumps in the S&P 500. But they're still enjoying some stock winners, too.

Very Young Investors Are Up Double-Digit Percentages On 10 Stocks

RINVOQ (upadacitinib) is now approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent1 The approval is based on the results of three Phase 3 studies: two for induction and one for maintenance 1,2 In these clinical trials, RINVOQ achieved the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8 in induction studies and week 52 in the maintenance study, and all secondary endpoints, including clinical response and mucosal healing 1,2 Safety results in ulcerative colitis were generally consistent with the known safety profile of RINVOQ, with no new important safety risks observed2,3-6 Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease (IBD) that can lead to substantial burden and often disability among patients. 7-9 At least 6.8 million people worldwide live with IBD, including ulcerative colitis10 The approval represents RINVOQ's fifth therapeutic indication in the EU NORTH CHICAGO, Ill.

European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis

Emerson Electric

Coca-Cola

Meeting the parameters to join the elite Dividend King group speaks volumes about these companies' well-established and thriving nature.

3 Dividend Kings Suited Perfectly for Income Investors

– Data analyses of onabotulinumtoxinA (BOTOX ® ) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use – Study results on onabotulinumtoxinA (BOTOX® Cosmetic) in moderate to severe forehead lines, lateral canthal lines, and glabellar lines to be presented – Company to share advances in aesthetic medicine, including investigational results from a Phase 2b study in patients with masseter muscle hypertrophy NORTH CHICAGO, Ill. , July 25, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Allergan Aesthetics announced today that more than 30 abstracts, including seven podium presentations, will be presented during the upcoming TOXINS 2022 Conference, July 27-30 in New Orleans.

AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference

Alphabet

Vici Properties

It's time to revisit these top picks as we are more than halfway through a tumultuous 2022. AbbVie and VICI have vastly outperformed the market, but Alphabet is struggling.

My Top 3 Picks For 2022 Revisited: 2 Huge Winners, But Google Falters

Barclays

D.R. Horton

Expedia

Leggett & Platt

Target

United Rentals

These value stocks trading at discount are trading at attractive valuations while their fundamentals continue to impress. The post 7 Value Stocks Trading at a Massive Discount Right Now appeared first on InvestorPlace.

7 Value Stocks Trading at a Massive Discount Right Now

Biogen

Bristol-Myers

Eli Lilly

The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier drug companies in the second half, including interest rates, federal drug pricing actions and scrutiny by the Federal Trade Commission.

2nd-Quarter Earnings Results Could Impact Drug Company Shares

AbbVie is within striking distance of a buy zone ahead of its next quarterly earnings report, expected on or around Jul. 29. The post Keep AbbVie Stock On Your Watch List Ahead Of Earnings appeared first on Investor's Business Daily.

Keep AbbVie Stock On Your Watch List Ahead Of Earnings

The healthcare company has been outperforming the S&P over the past decade by a wide margin.

Could AbbVie Stock Help You Retire a Millionaire?

Big Lots

Altria

Do you have these top high-yield dividend stocks on your watchlist right now?

3 High Yield Dividend Stocks To Watch Today

- Alliance will provide opportunity for AbbVie to further expand its diverse eye care portfolio and provide additional treatment options for glaucoma patients -  Collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates goal to bring MINIject to more patients globally - Deal terms include a $60M upfront payment to iSTAR Medical - iSTAR Medical to continue development and commercialization of the MINIject device up to completion of the U.S. PMA study NORTH CHICAGO, Ill. and WAVRE, Belgium , July 20, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical's MINIject® device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma.

AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma

Agree Realty

Enbridge

LTC Properties

Southern Copper

With inflation putting a beating on household budgets and earnings, the best income stocks to buy may help mitigate the crisis. The post 7 Best Income Stocks to Buy Now appeared first on InvestorPlace.

7 Best Income Stocks to Buy Now

AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that's exactly why it makes sense to add or hold in your bear market portfolio.

A Dose of AbbVie Stock Can Help Your Bear Market Portfolio

Abbott Labs

Johnson & Johnson

Recession or no recession, these well-established businesses are going to keep on growing.

3 Dividend Growth Stocks You Can Buy Now and Hold Forever

ABBV stock could have substantial room to run as a big-bank analyst assigns a high rating to relentlessly innovative AbbVie. The post $192 Price Target Makes AbbVie Stock a Notable Healthcare Pick appeared first on InvestorPlace.

$192 Price Target Makes AbbVie Stock a Notable Healthcare Pick

AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine.

News for AbbVie Stock (ABBV)